Cancer of unknown primary site

This phase 2 trial tests three immune-boosting drugs (cemiplimab, fianlimab, and ipilimumab) given before surgery in 20 people with advanced but removable melanoma. The goal is to see if the combination is safe and can shrink tumors, potentially improving outcomes. Participants m…

This phase 2 trial tests a new radioactive drug, Lu-177 FAP-2286, in 20 patients with cancer of unknown primary (CUP). The drug targets a protein found on cells near tumors, delivering radiation directly to the cancer. The main goal is to see if the treatment can shrink tumors or…

This study will test a special type of PET/CT scan called 18F-FAPI to see if it can better find where a cancer started when the original source is unknown. About 120 people with cancer of unknown primary will receive the scan, and researchers will measure how accurate it is at de…

This study explores the personal stories of people diagnosed with cancer of unknown primary (CUP) and their carers. Through interviews and focus groups, researchers aim to understand the emotional and practical challenges of living with this uncertain diagnosis. The findings will…

This study is for people with Cancer of Unknown Primary (CUP), where doctors can't find where the cancer started. The goal is to use advanced genetic tests on tumor samples to identify the cancer's origin. This information may help doctors choose more effective treatments and imp…

This study enrolls 30 people with cancer that has spread (metastasized). Researchers take a sample of the tumor and analyze its RNA to see if they can predict where the cancer originally started. No treatment is given; the goal is to see how accurate the RNA test is at identifyin…